Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

23/09 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
01/26/01	€0.2740	+4.98%	1,369
31/26/31	€0.2610	0.00%	15,919
28/26/28	€0.2610	-3.69%	8,559
27/26/27	€0.2710	+3.83%	22,588
26/26/26	€0.2610	+1.56%	21,999

Real-time Euronext Bruxelles

More quotes

Market Closed - Euronext Bruxelles 09:25:00 01/09/2026 pm IST			5-day change	1st Jan Change
0.2740 ^EUR	+4.98%		+4.58%	+61.18%

14/07	Celyad Oncology SA announced that it expects to receive ?0.5 million in funding from Fortress Investment Group LLC	CI
14/07	Celyad Oncology to Raise Funds via Private Placement	MT

Market Cap	1.23Cr 1.42Cr 1.15Cr 1.05Cr 1.98Cr 134.94Cr 1.99Cr 14Cr 5.31Cr 69Cr 5.34Cr 5.22Cr 227.6Cr	P/E 2024	-5.06x	P/E 2025	9.44x
Enterprise Value	1.06Cr 1.22Cr 99.3L 90.47L 1.7Cr 116.15Cr 1.71Cr 12Cr 4.57Cr 59Cr 4.59Cr 4.5Cr 195.91Cr	EV / Sales 2024	141x	EV / Sales 2025	281x
Free-Float	34.3%	Yield 2024 *	-	Yield 2025	-

14/07	Celyad Oncology SA announced that it expects to receive ?0.5 million in funding from Fortress Investment Group LLC	CI
14/07	Celyad Oncology to Raise Funds via Private Placement	MT
15/04	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
02/04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/25/30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
29/25/29	Celyad Oncology announces research facility divestiture	RE
29/25/29	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25/25/25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/25/26	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
29/25/29	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
28/25/28	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25/25/25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
24/25/24	Celyad Oncology Announces Strategic Review	CI

28/22/28	HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	MT
11/22/11	Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	MT
06/21/06	Celyad Oncology : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	MT
26/21/26	Celyad Oncology : JonesTrading Downgrades Celyad Oncology to Hold from Buy	MT
08/20/08	Celyad Oncology : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	MT

Celyad Oncology SA Share Price

Stocks

CYAD

BE0974260896

Biotechnology & Medical Research

Valuation : Celyad Oncology SA

Chart: Celyad Oncology SA

Latest news : Celyad Oncology SA

Analysts' recommendations : Celyad Oncology SA

Press Releases : Celyad Oncology SA

News in other languages : Celyad Oncology SA

Quotes and Performance

Price Extremes

Managers and Directors : Celyad Oncology SA

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

29/07	Celyad Oncology : Publication of a transparency notification received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)	PU
14/07	Celyad Oncology : Announces €500,000 Private Placement	PU
20/05	Celyad Oncology : AGM Minutes - informal translation EN	PU
02/04	Celyad Oncology : reports full year 2025 financial results and business highlights	PU
29/25/29	Celyad Oncology : Announces Research Facility Divestiture	PU

29/07	Celyad Oncology : Publication d’une notification de transparence reçue de Tolefi SA (Article 14§1 de la Loi du 2 Mai 2007)
18/07	Rustige start cijferseizoen in Brussel
14/07	Celyad kondigt private plaatsing van 500.000 euro aan
20/05	Celyad Oncology : AGO Procès Verbal - version FR
17/04	Celyad Oncology : Rapport Annuel 2025 FR

1 day	+4.98%
1 week	+4.58%
Current month	+4.98%
1 month	+4.98%
3 months	-5.52%
6 months	-29.74%
Current year	+61.18%

1 week	0.26	0.28
1 month	0.23	0.29
Current year	0.17	0.65
1 year	0.16	0.65
3 years	0.16	1.28
5 years	0.16	4.6
10 years	0.16	56.48

Manager	Title	Age	Since
David Georges DFI	Director of Finance/CFO	-	01/01/2019
An Phan LAW	General Counsel	51	01/09/2021

Director	Title	Age	Since
Michel Lussier CHM	Chairman	69	24/07/2007
Serge Goblet BRD	Director/Board Member	-	01/01/2008
Hilde Windels CHM	Chairman	61	23/06/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELYAD ONCOLOGY SA	+4.98%	+4.58%	-14.11%	-63.56%	1.36Cr
LONZA GROUP AG	+0.21%	-1.70%	+1.90%	+18.18%	4.98TCr
REVOLUTION MEDICINES, INC.	+2.09%	-0.71%	+430.91%	+498.77%	4.41TCr
IQVIA HOLDINGS INC.	-1.09%	-0.41%	+40.61%	+15.17%	4.3TCr
BEONE MEDICINES AG	-0.26%	-4.71%	+8.02%	+71.67%	4.09TCr
CELLTRION, INC.	-0.48%	-3.09%	+17.78%	+49.80%	3.31TCr
MEDPACE HOLDINGS, INC.	-1.81%	-5.02%	+23.21%	+113.24%	1.66TCr
ASCENDIS PHARMA A/S	-1.06%	+2.87%	-	-	1.73TCr
EUROFINS SCIENTIFIC SE	-1.35%	-2.32%	+10.40%	+25.90%	1.46TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.05%	-5.14%	+75.09%	+34.69%	1.38TCr
Average	-0.05%	-1.51%	+65.98%	+84.87%	2.73TCr
Weighted average by Cap.	-0.19%	-1.79%	+91.13%	+120.57%

	2024	2025
Net sales	2L 2L 2L 2L 3L 2.05Cr 3L 20.68L 8L 1.04Cr 8L 8L 3.45Cr	21T 24.35T 19.75T 18T 33.84T 23.1L 34.02T 2L 90.89T 11.75L 91.4T 89.42T 38.97L
Net income	-58.24L -67.52L -54.78L -49.91L -93.85L -64Cr -94.36L -6.48Cr -2.52Cr -33Cr -2.53Cr -2.48Cr -108.08Cr	8L 10L 8L 7L 13.38L 9.13Cr 13.45L 92.3L 35.92L 4.65Cr 36.13L 35.34L 15Cr
Net Debt	-32.95L -38.2L -30.99L -28.24L -53.1L -36Cr -53.39L -3.66Cr -1.43Cr -18Cr -1.43Cr -1.4Cr -61Cr	-17.08L -19.8L -16.07L -14.64L -27.52L -19Cr -27.67L -1.9Cr -73.93L -9.56Cr -74.34L -72.73L -32Cr